Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084682 · ClinicalTrials.gov registry record · Phase 2
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study of Stage IV Squamous Cell Carcinoma of the Hypopharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT00084682 is a Phase 2 study of Stage IV Squamous Cell Carcinoma of the Hypopharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00084682, a Phase 2 study of Stage IV Squamous Cell Carcinoma of the Hypopharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG romidepsin
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084682
The ClinicalTrials.gov registry entry for NCT00084682 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Squamous Cell Carcinoma of the Hypopharynx appearing as the primary indexed condition, and to 1 intervention - of which romidepsin is the first listed.
NCT00084682 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00084682 about?
NCT00084682 is a clinical study titled "Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or d...
What is the current status of trial NCT00084682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-06. Estimated completion is 2012-03.
What conditions does trial NCT00084682 study?
This clinical trial studies the following conditions: Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity.
What interventions are being tested in trial NCT00084682?
The interventions under investigation include: romidepsin (DRUG).
Who is sponsoring clinical trial NCT00084682?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00084682 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
COMPLETED · Phase 2
-
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Stage IV Squamous Cell Carcinoma of the Hypopharynx
All registered trials for this condition
Stage IV Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.